Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

Conditions

• Pediatric Hodgkin's Disease

Interventions

• RADIATION: No radiotherapy if CR at the end of chemotherapy.
• DRUG: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
• DRUG: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
• RADIATION: IN 30Gy RT in case of PR at the end of chemotherapy
• DRUG: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
• DRUG: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
• DRUG: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
• DRUG: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
• DRUG: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Sponsor

Hospital JP Garrahan